A meta-analysis of the polyunsaturated fatty acid composition of erythrocyte membranes in schizophrenia

Schizophrenia Research

Volumn 141, Issue 2-3, 2012, Pages 153-161

  van der Kemp, W J M ^a   Klomp, D W J ^a   Kahn, R S ^b   Luijten, P R ^a   Hulshoff Pol, H E ^b  

^a UNIVERSITY MEDICAL CENTER UTRECHT   (Netherlands)

^b UNIVERSITY MEDICAL CENTER UTRECHT   (Netherlands)

Author keywords

Brain volume loss; Erythrocyte; Fatty acid; Pufa; Schizophrenia

Indexed keywords

ADRENIC ACID; ARACHIDONIC ACID; ATYPICAL ANTIPSYCHOTIC AGENT; DOCOSAHEXAENOIC ACID; DOCOSAPENTAENOIC ACID; GAMMA LINOLENIC ACID; ICOSAPENTAENOIC ACID; LINOLEIC ACID; NEUROLEPTIC AGENT; POLYUNSATURATED FATTY ACID;

ADULT; ARTICLE; CONTROLLED STUDY; DISEASE DURATION; DRUG EFFICACY; DRUG SAFETY; ERYTHROCYTE MEMBRANE; FATTY ACID ANALYSIS; FEMALE; HUMAN; LIPID COMPOSITION; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; SCHIZOPHRENIA; SYSTEMATIC REVIEW; TREATMENT RESPONSE;

ANTIPSYCHOTIC AGENTS; CELL MEMBRANE; ERYTHROCYTES; FATTY ACIDS, UNSATURATED; FEMALE; HUMANS; MALE; SCHIZOPHRENIA;

EID: 84866900532     PISSN: 09209964     EISSN: 15732509     Source Type: Journal    
DOI: 10.1016/j.schres.2012.08.014     Document Type: Article

References (75)

1. Amminger G.P., Schäfer M.R., Papageorgiou K., Klier C.M., Cotton S.M., Harrigan S.M., Mackinnon A., McGorry P.D., Berger G.E. Long-chain ?-3 fatty acids for indicated prevention of psychotic disorders a randomized, placebo-controlled trial. Arch. Gen. Psychiatry 2010, 67:146-154.
2. Andreasen N.C., Nopoulos P., Magnotta V., Pierson R., Ziebell S., Ho B.C. Progressive brain change in schizophrenia: a prospective longitudinal study of first-episode schizophrenia. Biol. Psychiatry 2011, 70:672-679.
3. Arvindakshan M., Sitasawad S., Debsikdar V., Ghate M., Evans D., Horrobin D.F., Bennett C., Ranjekar P.K., Mahadik S.P. Essential polyunsaturated fatty acid and lipid peroxide levels in never-medicated and medicated schizophrenia patients. Biol. Psychiatry 2003, 53:56-64.
4. Assies J., Lieverse R., Vreken P., Wanders R.J.A., Dingemans P.M.J.A., Linszen D.H. Significantly reduced docosahexaenoic and docosapentaenoic acid concentrations in erythrocyte membranes from schizophrenic patients compared with a carefully matched control group. Biol. Psychiatry 2001, 49:510-522.
5. Bazan N.G. Synaptic signalling by lipids in the life and death of neurons. Mol. Neurobiol. 2005, 31:219-230.
6. Bitanihirwe B.K., Woo T.U. Oxidative stress in schizophrenia: an integrated approach. Neurosci. Biobehav. Rev. 2011, 35:878-893.
7. Borenstein M. Comprehensive Meta Analysis (Version 2) 2006, Biostat, Englewood, NJ.
8. Brown R., Colter N., Corsellis J.A., Crow T.J., Frith C.D., Jagoe R., Johnstone E.C., Marsh L. Postmortem evidence of structural brain changes in schizophrenia. Differences in brain weight, temporal horn area, and parahippocampal gyrus compared with affective disorder. Arch. Gen. Psychiatry 1986, 43:36-42.
9. Cahn W., Hulshoff Pol H.E., Lems E.B., Van Haren N.E., Schnack H.G., van der Linden J.A., Schothorst P.F., van Engeland H., Kahn R.S. Brain volume changes in firstepisode schizophrenia: a 1-year follow-up study. Arch. Gen. Psychiatry 2002, 59:1002-1010.
10. Cao Y., Pearman A.T., Zimmerman G.A., McIntyre T.M., Prescott S.M. Intracellular unesterified arachidonic acid signals apoptosis. Proc. Natl. Acad. Sci. U. S. A. 2000, 97:11280-11285.
11. Carlson S.E., Carver J.D., House S.G. High fat diets varying in ratios of polyunsaturated to saturated fatty acid and linoleic to linolenic acid: a comparison of rat neural and red cell membrane phospholipids. J. Nutr. 1986, 116:718-725.
12. Conklin S.M., Gianaros P.J., Brown S.M., Yao J.K., Hariri A.R., Manuck S.B., Muldoon M.F. Long-chain omega-3 fatty acid intake is associated positively with corticolimbic gray mattervolume in healthy adults. Neurosci. Lett. 2007, 421:209-212.
13. Connor W.E., Neuringer M., Lin D.S. Dietary effects on brain fatty acid composition: the reversibility of n-3 fatty acid deficiency and turnover of docosahexaenoic acid in the brain, erythrocytes, and plasma of rhesus monkeys. J. Lipid Res. 1990, 31:237-247.
14. DeLisi L.E., Hoff A.L., Sakuma M., et al. A prospective follow-up study of brain morphology and cognition in 1st episode schizophrenic patients. Biol. Psychiatry 1995, 38:349-360.
15. DeLisi L.E., Grimson R., Sakuma M., Tew W., Kushner M., Hoff A.L. Schizophrenia as a chronic active brain process: a study of progressive brain structural change subsequent to the onset of schizophrenia. Psychiatry Res. Neuroimaging 1997, 74:129-140.
16. DeLisi L.E., Szulc K.U., Bertisch H.C., Majacher M., Brown K. Understanding structural brain changes in schizophrenia. Dialogues Clin. Neurosci. 2006, 8:71-78.
17. Doris A.B., Wahle K., MacDonald A., Morris S., Coffey I., Muir W., Blackwood D. Red cell membrane fatty acids, cytosolic phospholipase-A2 and schizophrenia. Schizophr. Res. 1998, 31:185-196.
18. Evans D.R., Parikh V.V., Khan M.M., Coussons C., Buckley P.F., Mahadik S.P. Red blood cell membrane essential fatty acid metabolism in early psychotic patients following antipsychotic drug treatment. Prostaglandins Leukot. Essent. Fatty Acids 2003, 69:393-399.
19. Farooqui A.A. Lipid mediators in the neural cell nucleus: their metabolism, signalling, and association with neurological disorders. Neuroscientist 2009, 15:392-407.
20. Glantz L.A., Gilmore J.H., Lieberman J.A., Jarskog L.F. Apoptotic mechanisms and the synaptic pathology of schizophrenia. Schizophr. Res. 2006, 81:47-63.
21. Glen A.I.M., Ross B.M. Prostaglandins and eicosanoids in mental illness. The Eicosanoids 2004, 493-498. Wiley & Sons Ltd., Chichester. P. Curtis-Prior (Ed.).
22. Glen A.I., Glen E.M., Horrobin D.F., Vaddadi K.S., Spellman M., Morse-Fisher N., Ellis K., Skinner F.S. A red cell membrane abnormality in a subgroup of schizophrenic patients: evidence for two diseases. Schizophr. Res. 1994, 12:53-61.
23. Gur R.E., Cowell P., Turetsky B.I., Gallacher F., Cannon T., Bilker W., Gur R.C. A follow-up magnetic resonance imaging study of schizophrenia. Relationship of neuroanatomical changes to clinical and neurobehavioral measures. Arch. Gen. Psychiatry 1998, 55:145-152.
24. Hamill O.P., Martinac B. Molecular basis of mechanotransduction in living cells. Physiol. Rev. 2001, 81:685-740.
25. Hoffmann E.K., Lambert I.H., Pedersen S.F. Physiology of cell volume in vertebrates. Physiol. Rev. 2009, 89:193-277.
26. Horrobin D.F., Manku M.S., Hillman H., Iain A., Glen M. Fatty acid levels in the brains of schizophrenics and normal controls. Biol. Psychiatry 1991, 30:795-805.
27. Horrobin D.F., Glen A.I.M., Vaddadi K. Themembrane hypothesis of schizophrenia. Schizophr. Res. 1994, 13:195-207.
28. Horrobin D.F. Themembrane phospholipid hypothesis as a biochemical basis for the neurodevelopmental concept of schizophrenia. Schizophr. Res. 1998, 30:193-208.
29. Hulshoff Pol H.E., Kahn R.S. What happens after the first episode? A review of progressive brain changes in chronically ill patients with schizophrenia. Schizophr. Bull. 2008, 34:354-366.
30. Hulshoff Pol H.E., Schnack H.G., Bertens M.G.B.C., van Haren N.E.M., van der Tweel I., Staal W.G., Baaré W.F.C., Kahn R.S. Gray matter volume changes in schizophrenia. Am. J. Psychiatry 2002, 159:244-250.
31. Johnstone E.C., Owens D.G.C. Early studies of brain anatomy in schizophrenia. Schizophrenia from Neuroimaging to Neuroscience 2004, 1-19. Oxford University Press, UK. S.M. Lawrie, E.C. Johnston, D.R. Weinberger (Eds.).
32. Kale A., Joshi S., Naphade N., Sapkale S., Raju M.S.V.K., Pillai A., Nasrallah H., Mahadik S.P. Opposite changes in predominantly docosahexaenoic acid (DHA) in cerebrospinal fluid and red blood cells from never-medicated first-episode psychotic patients. Schizophr. Res. 2008, 98:295-301.
33. Kemperman R.F.J., Veurink M., van der Wal T., Knegtering H., Bruggeman R., Fokkema M.R., Kema I.P., Korf J., Muskiet F.A.J. Low essential fatty acid and B-vitamin status in a subgroup of patients with schizophrenia and its response to dietary supplementation. Prostaglandins Leukot. Essent. Fatty Acids 2006, 74:75-85.
34. Khan M.M., Evans D.R., Gunna V., Scheffer R.E., Parikh V.V., Mahadik S.P. Reduced erythrocyte membrane essential fatty acids and increased lipid peroxides in schizophrenia at the never-medicated first-episode of psychosis and after years of treatment with antipsychotics. Schizophr. Res. 2002, 58:1-10.
35. Kropp S., Kern V., Lange K., Degner D., Hajak G., Kornhuber J., Rüther E., Emrich M.D.H.M., Schneider U., Bleich S. Oxidative stress during treatment with first and second-generation antipsychotics. J. Neuropsychiatry Clin. Neurosci. 2005, 17:227-231.
36. Lambert I.H. Regulation of the cellular content of the organic osmolyte taurine in mammalian cells. Neurochem. Res. 2004, 29:27-63.
37. Landén M., Davidsson P., Gottfries C.G., Månsson J.E., Blennow K. Reduction of the synaptophysin level but normal levels of glycerophospholipids in the gyrus cinguli in schizophrenia. Schizophr. Res. 2002, 55:83-88.
38. Laugharne J.D., Mellor J.E., Peet M. Fatty acids and schizophrenia. Lipids 1996, 31:S163-S165. (Suppl.).
39. Law M.H., Cotton R.G., Berger G.E. The role of phospholipases A2 in schizophrenia. Mol. Psychiatry 2006, 11:547-556.
40. Lieberman J.A., Tollefson G.D., Charles C., Zipursky R., Sharma T., Kahn R.S., Keefe R.S.E., Green A.I., Gur R.E., McEvoy J., Perkins D., Hamer R.M., Gu H., Tohen M. Antipsychotic drug effects on brain morphology in first-episode psychosis. Arch. Gen. Psychiatry 2005, 62:361-370.
41. Lukiw W.J., Bazan N.G. Inflammatory, apoptotic, and survival gene signaling in Alzheimer's disease. A review on the bioactivity of neuroprotectin D1 and apoptosis. Mol. Neurobiol. 2010, 42:10-16.
42. Mathalon D.H., Sullivan E.V., Lim K.P., Pfefferbaum A. Progressive brain volume changes and the clinical course of schizophrenia in men: a longitudinal magnetic resonance imaging study. Arch. Gen. Psychiatry 2001, 58:148-157.
43. McNamara R.K., Carlson S.E. Role of omega-3 fatty acids in brain development and function: Potential implications for the pathogenesis and prevention of psychopathology. Prostaglandins Leukot. Essent. Fatty Acids 2006, 75:329-349.
44. McNamara R.K., Jandacek R., Rider T., Tso P., Hahn C.-G., Richtand N.M., Stanford K.E. Abnormalities in the fatty acid composition of the post-mortem orbitofrontal cortex of schizophrenic patients: Gender differences and partial normalization with antipsychotic medications. Schizophr. Res. 2007, 91:37-50.
45. McNamara R.K., Liu Y., Jandacek R., Rider T., Tso P. The aging human orbitofrontal cortex: decreasing polyunsaturated fatty acid composition and associated increases in lipogenic gene expression and stearoyl-CoA desaturase activity. Prostaglandins Leukot. Essent. Fatty Acids 2008, 78:293-304.
46. Nigam S., Schewe T. Phospholipase A2s and lipid peroxidation. Biochim. Biophys. Acta 2000, 1488:167-181.
47. Obi F.O., Nwanze E.A. Fatty acid profiles in mental disease. Part 1. Linolenate variations in schizophrenia. J. Neurol. Sci. 1979, 43:447-454.
48. Olabi B., Ellison-Wright I., McIntosh A.M., Wood S.J., Bullmore E., Lawrie S.M. Are there progressive brain changes in schizophrenia? A meta-analysis of structural magnetic resonance imaging studies. Biol. Psychiatry 2011, 70:88-96.
49. Padurariu M., Ciobica A., Dobrin I., Stefanescu C. Evaluation of antioxidant enzymes activities and lipid peroxidation in schizophrenic patients treated with typical and atypical antipsychotics. Neurosci. Lett. 2010, 479:317-320.
50. Palacios-Pelaez R., Lukiw W.J., Bazan N.G. Omega-3 essential fatty acids modulate initiation and progression of neurodegenerative disease. Mol. Neurobiol. 2010, 41:367-374.
51. Peet M., Laugharne J., Rangarajan N., Horrobin D., Reynolds G. Depleted red cell membrane essential fatty acids in drug-treated schizophrenic patients. J. Psychiatr. Res. 1995, 29:227-232.
52. Peet M., Laugharne J.D.E., Mellor J., Ramchand C.N. Essential fatty acid deficiency in erythrocyte membranes from chronic schizophrenic patients, and the clinical effects of dietary supplementation. Prostaglandins Leukot. Essent. Fatty Acids 1996, 55:71-75.
53. Peet M., Shah S., Selvam K., Ramchand C.N. Polyunsaturated fatty acid levels in red cell membranes of unmedicated schizophrenic patients. World J. Biol. Psychiatry 2004, 5:92-99.
54. Rajkowska G., Selemon L.D., Goldman-Rakic P.S. Neuronal and glial somal size in the prefrontal cortex: a postmortem morphometric study of schizophrenia and Huntington disease. Arch. Gen. Psychiatry 1998, 55:215-224.
55. Ranjekar P.K., Hinge A., Hegde M.V., Ghate M., Kale A., Sitasawad S., Wagh U.V., Debsikdar V.B., Mahadik S.P. Decreased antioxidant enzymes and membrane essential polyunsaturated fatty acids in schizophrenic and bipolar mood disorder patients. Psychiatry Res. 2003, 121:109-122.
56. Rapoport J.L., Giedd J.N., Blumenthal J., Hamburger S., Jeffries N., Fernandez T., Nicolson R., Bedwell J., Lenane M., Zijdenbos A., Paus T., Evans A. Progressive cortical change during adolescence in childhood-onset schizophrenia. A longitudinal magnetic resonance imaging study. Arch. Gen. Psychiatry 1999, 56:649-654.
57. Reddy R.D., Keshavan M.S. Phosphorus magnetic resonance spectroscopy: its utility in examining the membrane hypothesis of schizophrenia. Prostaglandins Leukot. Essent. Fatty Acids 2003, 69:401-405.
58. Reddy R.D., Keshavan M.S., Yao J.K. Reduced red blood cell membrane essential polyunsaturated fatty acids in first episode schizophrenia at neuroleptic-naive baseline. Schizophr. Bull. 2004, 30:901-911.
59. Sethom M.M., Fares S., Bouaziz N., Melki W., Jemaa R., Feki M., Hechmi Z., Kaabachi N. Poly-unsaturatedfattyacids deficits are associated with psychotic state and negative symptoms in patients with schizophrenia. Prostaglandins Leukot. Essent. Fatty Acids 2010, 83:131-136.
60. Smesny S., Milleit B., Nenadic I., Preul C., Kinder D., Lasch J., Willhardt I., Sauer H., Gaser C. Phospholipase A2 activity is associated with structural brain changes in schizophrenia. Neuroimage 2010, 52:1314-1327.
61. Sumiyoshi T., Matsui M., Itoh H., Higuchi Y., Arai H., Takamiya C., Kurachi M. Essential polyunsaturated fatty acids and social cognition in schizophrenia. Psychiatry Res. 2008, 157:87-93.
62. Sumiyoshi T., Higuchi Y., Matsui M., Itoh H., Uehara T., Itoh T., Arai H., Takamiya C., Suzuki M., Kurachi M. Membrane fatty acid levels as a predictor of treatment response in chronic schizophrenia. Psychiatry Res. 2011, 186:23-27.
63. Vaddadi K.S., Gilleard C.J., Mindham R.H., Butler R. A controlled trial of prostaglandin E1 precursor in chronic neuroleptic resistant schizophrenic patients. Psychopharmacology (Berl) 1986, 88:362-367.
64. Vaddadi K.S., Courtney P., Gilleard C.J., Manku M.S., Horrobin D.F. A double-blind trial of essential fatty acid supplementation in patients with tardive dyskinesia. Psychiatry Res. 1989, 27:313-323.
65. van Haren N.E., Hulshoff Pol H.E., Schnack H.G., Cahn W., Brans R., Carati I., Rais M., Kahn R.S. Progressive brain volume loss in schizophrenia over the course of the illness: evidence of maturational abnormalities in early adulthood. Biol. Psychiatry 2008, 63:106-113.
66. van Haren N.E., Schnack H.G., Cahn W., van den Heuvel M.P., Lepage C., Collins L., Evans A.C., Hulshoff Pol H.E., Kahn R.S. Arch. Gen. Psychiatry 2011, 68:871-880.
67. Waldo M.C., Kuypers E., Cawthra E., Larkin S. Fatty acid metabolism in schizophrenia: comparison of the effects of prolizin and clozapine. Schizophr. Res. 2003, 60(Suppl. 317).
68. Wood S.J., Velakoulis D., Smith D.J., Bond D., Stuart G.W., McGorry P.D., Brewer W.J., Bridle N., Eritaia J., Desmond P., Singh B., Copolov D., Pantelis C. A longitudinal study of hippocampal volume in first episode psychosis and chronic schizophrenia. Schizophr. Res. 2001, 52:37-46.
69. Wright I.C., Rabe-Hesketh S., Woodruff P.W.R., David A.S., Murray R.M., Bullmore E.T. Meta-Analysis of Regional Brain Volumes in Schizophrenia. Am. J. Psychiatry 2000, 157:16-25.
70. Yagami T., Ueda K., Asakura K., Hata S., Kuroda T., Sakaeda T., Takasu N., Tanaka K., Gemba T., Hori Y. Human group IIA secretory phospholipase A2 induces neuronal cell death via apoptosis. Mol. Pharmacol. 2002, 61:114-126.
71. Yamashima T. A putative link of PUFA, GPR40 and adult-born hippocampal neurons for memory. Prog. Neurobiol. 2008, 84:105-115.
72. Yao J.K., van Kammen D.P., Welker J.A. Red blood cell membrane dynamics in schizophrenia: II. Fatty acid composition. Schizophr. Res. 1994, 13:217-226.
73. Yao J.K., Leonard S., Reddy R.D. Membrane phospholipid abnormalities in postmortem brains from schizophrenic patients. Schizophr. Res. 2000, 42:7-17.
74. Yao J.K., Stanley J.A., Reddy R.D., Keshavan M.S., Pettegrew J.W. Correlations between peripheral polyunsaturated fatty acid content and in vivo membrane phospholipid metabolites. Biol. Psychiatry 2002, 52:823-830.
75. Yao J.K., Thomas E.A., Reddy R.D., Keshavan M.S. Association of plasma apolipoproteins D with RBC membrane arachidonic acid levels in schizophrenia. Schizophr. Res. 2005, 72:259-266.